ENGLEWOOD, Colo., April 27, 2022 /PRNewswire/ -- Ampio
Pharmaceuticals, Inc. (NYSE American: AMPE), a
biopharmaceutical company focused on the advancement of
immunomodulatory therapies for the treatment of pain resulting from
osteoarthritis in the knee and potentially other articular
joints, announced that the Company will be hosting a
conference call on April 28, 2022 at
8am EDT regarding the update from the
Food and Drug Administration with respect to its AP-013
study.
Conference Call Details
Date/Time: April 28, 2022
at 8am EDT
Title: Investor Update Call - FDA Response Letter AP-013
Study
Conference Link:
https://event.on24.com/wcc/r/3769445/94EB73B2CBD066B2B00A61BEA2BC8A2E
Toll Free dial-in
number:
|
1 (888)
210-3346
|
Local dial-in
number:
|
1 (646)
960-0253
|
Conference ID:
|
5564580
|
*Participants will need to enter the conference ID before
being met by an operator. A recording of the call will be available
on the Ampio website.
About Ampio Pharmaceuticals
Ampio Pharmaceuticals, Inc. is a biopharmaceutical company
primarily focused on the advancement of immunology-based therapies
for the treatment of pain resulting from osteoarthritis. Ampio's
lead drug, Ampion™, is backed by an extensive patent portfolio with
intellectual property protection extending through 2037 and may be
eligible for 12-year FDA market exclusivity upon approval as a
novel biologic under the Biologics Price Competition and Innovation
Act (BPCIA).
Forward Looking Statements
Ampio's statements in this press release and the webinar that
are not historical fact, and that relate to future plans or events,
are forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995. Forward-looking
statements can be identified by the use of words such as "believe,"
"expect," "plan," "anticipate," and similar expressions. These
forward-looking statements include statements regarding Ampio's
expectations with respect to Ampion and its classification, as well
as those associated with regulatory approvals and other FDA
decisions, the Biological License Application (BLA), the ability of
Ampio to enter into partnering arrangements, clinical trials and
decisions and changes in business conditions and similar events,
the ability to receive regulatory approval to conduct clinical
trials, that Ampion may be used to treat ARDS induced by COVID-19,
all of which are inherently subject to various risks and
uncertainties. The risks and uncertainties involved include those
detailed from time to time in Ampio's filings with the Securities
and Exchange Commission, including without limitation, under
Ampio's Annual Report on Form 10-K and other documents filed with
the Securities and Exchange Commission. Ampio undertakes no
obligation to revise or update these forward-looking statements,
whether as a result of new information, future events or
otherwise.
Investor and Media Contacts:
Tony Russo or Nic Johnson
Russo Partners
info@ampiopharma.com
tony.russo@russopartnersllc.com
nic.johnson@russopartnersllc.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/ampio-pharmaceuticals-inc-to-hold-conference-call-301534735.html
SOURCE Ampio Pharmaceuticals, Inc.